Gaurav Singh, MD MPH

For a functional older patient with recurrent, infiltrative disease after repeated excisions, multidisciplinary review supports hedgehog inhibition with curative intent and a potential path toward less morbid definitive treatment.

Class-wide laboratory monitoring, a predictable adverse event timeline, and emerging resistance mechanisms shape how hedgehog inhibitor therapy is initiated, sustained, and eventually complemented by agents in development.

Distinct pharmacokinetic profiles, including volume of distribution, half-life, and time to steady state, differentiate the two approved hedgehog inhibitors and can be translated into patient-facing counseling during shared decision-making.

Multimodal planning for advanced basal cell carcinoma extends beyond labeled indications, with neoadjuvant hedgehog inhibition, adjuvant radiation, and immune checkpoint inhibitors each occupying a defined place in treatment sequencing.

Although hedgehog pathway inhibitors are considered first-line systemic therapy for locally advanced disease, surgical fatigue and patient preference may warrant earlier discussion of oral treatment than current practice patterns reflect.

Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.

See how gene expression profiling bridges guideline gaps in high‑risk skin SCC, guiding radiation, follow‑up, and precision treatment decisions.

Gene expression profiling refines cutaneous SCC risk beyond guidelines, influencing surveillance, radiation decisions, and neoadjuvant immunotherapy.

Explore cutaneous SCC care from topical therapies and Mohs to adjuvant radiation and PD-1 immunotherapy, guided by shared decisions and profiling.

Learn how cutaneous SCC care shifts from topical therapy to Mohs, radiation, and PD-1 immunotherapy, guided by shared decisions and profiling.

Learn why gene expression profiling in cutaneous SCC can’t yet guide imaging or radiation decisions—and what evidence gaps still limit its use.

Gene expression profiling flags hidden high-risk cutaneous

RNA gene-expression profiling from biopsy stratifies cutaneous squamous cell cancer metastasis risk, guiding surveillance and adjuvant radiation.

Learn when gene expression profiling reshapes cutaneous SCC risk, guiding radiation, imaging, and follow-up beyond traditional staging.

How 41-gene profiling and ctDNA reshape cutaneous SCC care, guiding radiation, imaging, and tighter follow-up for hidden high-risk tumors.

How 41-gene profiling and ctDNA refine cutaneous SCC risk after Mohs, guiding radiation, imaging, and tighter follow-up.

Dermatologist shortages delay squamous cell cancer detection; learn practical screening and risk cues that help catch aggressive tumors earlier.

How dermatologists size up suspected cutaneous SCC—site, size, risk factors, pathology—to rank risk and choose the right treatment.

This episode examines the diagnostic workflow for cutaneous squamous cell carcinoma (cSCC), emphasizing how clinical, pathological, and patient-specific factors inform risk assessment, prognostication, and individualized management strategies.

This episode reviews the rising burden of cutaneous squamous cell carcinoma (cSCC), highlighting key risk factors, variable clinical presentations, and the growing role of molecular profiling tools in improving risk assessment and clinical decision-making.